LOGIN
TNF antagonist better in treatment of early rheumatoid arthritis
May 2013
TNF antagonist better in treatment of early rheumatoid arthritis
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
Lancet. 2009 Aug 8;374(9688):459-66.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
258 patients with early stage rheumatoid arthritis, who were unresponsive to 4 months treatment with methotrexate, were randomized to receive additional treatment with Infliximab (tumor necrosis factor antagonist) or sulfasalazine and hydroxychloroquine. This trial assessed the efficacy of the use of tumor necrosis factor antagonists in treatment of rheumatoid arthritis, while comparing this treat...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.